Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system).
In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the disease can cause the nerves themselves to deteriorate or become permanently damaged.
Signs and symptoms of MS vary widely and depend on the amount of nerve damage and which nerves are affected. Some people with severe MS may lose the ability to walk independently or at all, while others may experience long periods of remission without any new symptoms.
How are Mesenchymal Stem Cells (MSC) administered in Multiple Sclerosis?
A typical treatment is as following; stem cells are administered by a license physician.
Medical evaluation and blood testing (Day 1)
Hyperbaric chamber (Day 2)
1 intrathecal injection and intravenous injection of Stem Cells (Day 3)
How can Stem Cells Help Multiple Sclerosis?
From what we know so far about stem cells and MS, there are two main ways that potential treatments for MS might be developed:
Immunomodulation – preventing immune damage to the nervous system
Remyelination – repairing the myelin sheath that has already been damaged
These are both considered ‘neuroprotective’ therapies because they aim to protect the nerve fibres inside the myelin sheath.
Because MS is a neurodegenerative disease, and its more prominent feature is the damage the disease does to the central nervous system, it is hoped that stem cells may hold the key to reversing the damage done by facilitating the repair of damaged nerve cells.
Which Kinds of cells are used in Multiple Sclerosis and how are they obtained?
Adult stem cells are obtained from ITC bank from donor tissue or autologous transplant, which is harvested from the patient’s own adipose tissue and it takes 21 days to culture, differentiate and administer the adult stem cells to the patient.
Multiple sclerosis - Mayo Clinic. (2016). Mayoclinic.org. Retrieved 5 May 2016, from
Med Clin (Barc). 2014 Mar 14. pii: S0025-7753(14)00082-7. Immunomodulatory properties of stem mesechymal cells in autoimmune diseases. [Article in Spanish] Sánchez-Berná II, Santiago-Díaz C2, Jiménez-Alonso J2.
Freedman, M., Bar-Or, A., Atkins, H., Karussis, D., Frassoni, F., & Lazarus, H. et al. (2010). The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Multiple Sclerosis, 16(4), 503-510.
Patani, R. & Chandran, S. (2012). Experimental and Therapeutic Opportunities for Stem Cells in Multiple Sclerosis. IJMS, 13(12), 14470-14491.
Harris, V., Faroqui, R., Vyshkina, T., & Sadiq, S. (2012). Characterization of Autologous Mesenchymal Stem Cell-Derived Neural Progenitors as a Feasible Source of Stem Cells for Central Nervous System Applications in Multiple Sclerosis. Stem Cells Translational Medicine, 1(7), 536-547.